Cooley LLP
We are only able to display limited information for this firm. We display more complete information for all of the following firms:
Cooley LLP has a strong track record advising global life sciences and healthcare companies, with many of the well-experienced team members leveraging advanced degrees in biology, pharmaceuticals and biotechnology. Key practice strengths include cross-border transactions, IPOs, M&A and licensing matters, as well as assisting investors and investment banks on strategic transactions. Shanghai-based Yiming Liu is well-regarded among leading healthcare founders, bankers and investors for his expertise in private financings, capital markets transactions, M&A and licensing matters. Patrick Loofbourrow splits his time between Singapore and Shanghai, reputed for his corporate practice, frequently acting for biotech and pharmaceutical companies on complex high-value transactions.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘The Cooley team has the broadest coverage in geographic practice and business functions, including financing, IP, human resources, benefits and deal transactions. ’
‘Patrick Loofbourrow is outstanding. He's highly professional, responsive, approachable and very thorough. ’
Key clients
- Akeso Inc.
- Angitia
Work highlights
Advised FutureGen on its US$1.8 billion license agreement with AbbVie to develop FG-M701, a next-generation TL1A antibody for the treatment of IBD currently in preclinical development.


